Hereditary angioedema: A brief review of new developments

Current Medical Research and Opinion

Volumn 30, Issue 5, 2014, Pages 923-930

  Altman, Katherine A ^a   Naimi, David R ^b  

^a Touro University California   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Bradykinin; C1 esterase inhibitor; C1 inhibitor; Hereditary angioedema; Prophylaxis; Recombinant C1 inhibitor; Treatment

Indexed keywords

ANTIHISTAMINIC AGENT; BRADYKININ; COMPLEMENT COMPONENT C1R; COMPLEMENT COMPONENT C1S; COMPLEMENT COMPONENT C1S INHIBITOR; DANAZOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ECALANTIDE; ECALLANTIDE; FRESH FROZEN PLASMA; ICATIBANT; KALLIKREIN; KALLIKREIN INHIBITOR; STANOZOLOL; UNCLASSIFIED DRUG;

ABDOMINAL SWELLING; ANGIONEUROTIC EDEMA; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; FACE EDEMA; HUMAN; NAUSEA; PATHOPHYSIOLOGY; REVIEW; VOMITING;

ANGIOEDEMAS, HEREDITARY; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84899055802     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.879441     Document Type: Review

References (76)

1. Roche O, Blanch A, Caballero T, et al. Hereditary angioedema due to C1 inhibitor deficiency: Patient registry and approach to the prevalence in Spain. Ann Allergy Asthma Immunol 2005;94:498-503
2. Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010;6:24
3. Lumry WR. Overview of epidemiology, pathophysiology, and disease progression in hereditary angioedema. Am J Manag Care 2013;19(7 Suppl):s103-10
4. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med 2008;359:1027-36
5. Bissler JJ, Cicardi M, Donaldson VH, et al. A cluster of mutations within a short triplet repeat in the C1 inhibitor gene. Proc Natl Acad Sci USA 1994;91:9622-5
6. Cicardi M, Agostoni A. Hereditary angioedema. N Engl J Med 1996;334: 1666-7
7. Bowen B, Hawk JJ, Sibunka S, et al. A review of the reported defects in the human C1 esterase inhibitor gene producing hereditary angioedema including four new mutations. Clin Immunol 2001;98:157-63
8. Pappalardo E, Cicardi M, Duponchel C, et al. Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema. J Allergy Clin Immunol 2000;106:1147-54
9. Gompels MM, Lock RJ, Abinun M, et al. C1 inhibitor deficiency: Consensus document. Clin Exp Immunol 2005;139:379-94
10. Cicardi M, Igarashi T, Rosen FS, et al. Molecular basis for the deficiency of complement 1 inhibitor in type I hereditary angioneurotic edema. J Clin Invest 1987;79:698-702
11. Davis 3rd AE, Aulak K, Parad RB, et al. C1 inhibitor hinge region mutations produce dysfunction by different mechanisms. Nat Genet 1992;1:354-8
12. Banerji A. Hereditary angioedema: Classification, pathogenesis, and diagnosis. Allergy Asthma Proc 2011;32:403-7
13. Tosi M. Molecular genetics of C1 inhibitor. Immunobiology 1998;199:358-65
14. Georgy MS, Pongracic JA. Hereditary and acquired angioedema. Allergy Asthma Proc 2012;33(Suppl 1):73-6
15. Bernstein JA. Update on angioedema: Evaluation, diagnosis, and treatment. Allergy Asthma Proc 2011;32:408-12
16. Busse PJ. Angioedema: Differential diagnosis and treatment. Allergy Asthma Proc 2011;32(Suppl 1):S3-11
17. Donaldson VH, Evans RR. A biochemical abnormality in hereditary angioneurotic edema: Absence of serum inhibitor of C' 1-esterase. Am J Med 1963;35:37-44
18. Bork K, Gul D, Hardt J, et al. Hereditary angioedema with normal C1 inhibitor: Clinical symptoms and course. Am J Med 2007;120:987-92
19. Bork K, Barnstedt SE, Koch P, et al. Hereditary angioedema with normal C1- inhibitor activity in women. Lancet 2000;356:213-17
20. Binkley KE, Davis 3rd A. Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. J Allergy Clin Immunol 2000;106:546-50
21. Martin L, Degenne D, Toutain A, et al. Hereditary angioedema type III: An additional French pedigree with autosomal dominant transmission. J Allergy Clin Immunol 2001;107:747-8
22. Bork K, Fischer B, Dewald G. Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy. Am J Med 2003;114:294-8
23. van Geffen M, Cugno M, Lap P, et al. Alterations of coagulation and fibrinolysis in patients with angioedema due to C1-inhibitor deficiency. Clin Exp Immunol 2012;167:472-8
24. Nussberger J, Cugno M, Cicardi M, et al. Local bradykinin generation in hereditary angioedema. J Allergy Clin Immunol 1999;104:1321-2
25. Cugno M, Nussberger J, Cicardi M, et al. Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol 2003;3:311-17
26. Bork K, Frank J, Grundt B, et al. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol 2007;119:1497-503
27. Bossi F, Fischetti F, Regoli D, et al. Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency. J Allergy Clin Immunol 2009;124:1303-10 e4
28. Wagenaar-Bos IG, Drouet C, Aygoren-Pursun E, et al. Functional C1-inhibitor diagnostics in hereditary angioedema: Assay evaluation and recommendations. J Immunol Methods 2008;338:14-20
29. Agostoni A, Aygoren-Pursun E, Binkley KE, et al. Hereditary and acquired angioedema: Problems and progress: Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004;114(3 Suppl):S51-131
30. Binkley KE, Davis 3rd AE. Estrogen-dependent inherited angioedema. Transfus Apher Sci 2003;29:215-19
31. Bork K, Gul D, Dewald G. Hereditary angio-oedema with normal C1 inhibitor in a family with affected women and men. Br J Dermatol 2006;154:542-5
32. Zuraw BL, Bork K, Binkley KE, et al. Hereditary angioedema with normal C1 inhibitor function: Consensus of an international expert panel. Allergy Asthma Proc 2012;33:S145-56
33. Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 2006;343:1286-9
34. Bork K, Wulff K, Meinke P, et al. A novel mutation in the coagulation factor 12 gene in subjects with hereditary angioedema and normal C1-inhibitor. Clin Immunol 2011;141:31-5
35. Cichon S, Martin L, Hennies HC, et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006;79:1098-104
36. Bouillet L, Ponard D, Rousset H, et al. A case of hereditary angio-oedema type III presenting with C1-inhibitor cleavage and a missense mutation in the F12 gene. Br J Dermatol 2007;156:1063-5
37. Bell CG, Kwan E, Nolan RC, et al. First molecular confirmation of an Australian case of type III hereditary angioedema. Pathology 2008;40:82-3
38. Nagy N, Greaves MW, Tanaka A, et al. Recurrent European missense mutation in the F12 gene in a British family with type III hereditary angioedema. J Dermatol Sci 2009;56:62-4
39. Prieto A, Tornero P, Rubio M, et al. Missense mutation Thr309Lys in the coagulation factor XII gene in a Spanish family with hereditary angioedema type III. Allergy 2009;64:284-6
40. Farkas H, Harmat G, Fay A, et al. Erythema marginatum preceding an acute oedematous attack of hereditary angioneuroticoedema. Acta Derm Venereol 2001;81:376-7
41. Starr JC, Brasher GW. Erythema marginatum preceding hereditary angioedema. J Allergy Clin Immunol 1974;53:352-5
42. Williamson DM. Reticulate erythema - A prodrome in hereditary angiooedema. Br J Dermatol 1979;101:549-52
43. Yucelten D, Kus S. Chicken-wire erythema, but not urticaria, as the presenting sign of hereditary angioedema. Eur J Dermatol 2006;16:197-8
44. Bork K, Meng G, Staubach P, et al. Hereditary angioedema: New findings concerning symptoms, affected organs, and course. Am J Med 2006;119:267-74
45. Gower R. HAE update: Determining optimal patient specific therapy. Allergy Asthma Proc 2013;34:7-12
46. Zuraw BL. Diagnosis and management of hereditary angioedema: An American approach. Transfus Apher Sci 2003;29:239-45
47. Zuraw BL. Current and future therapy for hereditary angioedema. Clin Immunol 2005;114:10-16
48. Pekdemir M, Ersel M, Aksay E, et al. Effective treatment of hereditary angioedema with fresh frozen plasma in an emergency department. J Emerg Med 2007;33:137-9
49. Gower RG, Lumry WR, Davis-Lorton MA, et al. Current options for prophylactic treatment of hereditary angioedema in the United States: Patient-based considerations. Allergy Asthma Proc 2012;33:235-40
50. Cicardi M, Bork K, Caballero T, et al; HAWK (Hereditary Angioedema International Working Group). Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: Consensus report of an International Working Group. Allergy 2012;67:147-57
51. Zuraw B, Cicardi M, Levy RJ, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 2010;126:821-7 e14
52. Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010;363:513-22
53. Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 2009;124:801-8
54. Bork K, Barnstedt SE. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med 2001;161:714-18
55. Craig TJ, Wasserman RL, Levy RJ, et al. Prospective study of rapid relief provided by C1 esterase inhibitor in emergency treatment of acute laryngeal attacks in hereditary angioedema. J Clin Immunol 2010;30:823-9
56. Bork K, Steffensen I, Machnig T. Treatment with C1-esterase inhibitor concentrate in type I or II hereditary angioedema: A systematic literature review. Allergy Asthma Proc 2013;34:312-27
57. Cicardi M, Levy RJ, McNeil DL, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 2010;363:523-31
58. Levy RJ, Lumry WR, McNeil DL, et al. EDEMA4: A phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol 2010;104:523-9
59. Sheffer AL, Macginnitie AJ, Campion M, et al. Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks. Ann Allergy Asthma Immunol 2013;110:184-8
60. MacGinnitie AJ, Campion M, Stolz LE, et al. Ecallantide for treatment of acute hereditary angioedema attacks: Analysis of efficacy by patient characteristics. Allergy Asthma Proc 2012;33:178-85
61. Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykininreceptor antagonist, in hereditary angioedema. N Engl J Med 2010;363:532-41
62. Gelfand JA, Sherins RJ, Alling DW, et al. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med 1976;295:1444-8
63. Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: A long-term survey of 118 patients. Ann Allergy Asthma Immunol 2008;100:153-61
64. Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med 1996;334:1630-4
65. Levi M, Choi G, Picavet C, et al. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol 2006;117:904-8
66. Grant JA, White MV, Li HH, et al. Preprocedural administration of nanofiltered C1 esterase inhibitor to prevent hereditary angioedema attacks. Allergy Asthma Proc 2012;33:348-53
67. Craig T, Pürsün EA, Bork K, et al. WAO guideline for the management of hereditary angioedema. World Allergy Organ J 2012;5:182-99
68. Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: Biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992;71:206-15
69. Gelfand JA, Boss GR, Conley CL, et al. Acquired C1 esterase inhibitor deficiency and angioedema: A review. Medicine (Baltimore) 1979;58:321-8
70. Cicardi M, Saini S, Feldweg AM. Acquired C1 inhibitor deficiency: Clinical manifestations, epidemiology, pathogenesis, and diagnoses. UpToDate 2013
71. Alsenz J, Bork K, Loos M. Autoantibody-mediated acquired deficiency of C1 inhibitor. N Engl J Med 1987;316:1360-6
72. Banerji A, Clark S, Blanda M, et al. Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department. Ann Allergy Asthma Immunol 2008;100:327-32
73. Miller DR, Oliveria SA, Berlowitz DR, et al. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension 2008;51:1624-30
74. Makani H, Messerli FH, Romero J, et al. Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. Am J Cardiol 2012;110:383-91
75. Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy 2011;66:317-30
76. Xu YY, Buyantseva LV, Agarwal NS, et al. Update on treatment of hereditary angioedema. Clin Exp Allergy 2013;43:395-405.